Development of glycan???targeted nanoparticles as a novel therapeutic opportunity for gastric cancer treatment

dc.creatorSANTOS, SOFIA N. dos
dc.creatorGUSHIKEN JUNIOR, DINO S.
dc.creatorPEREIRA, JHONATAS P.M.
dc.creatorIADOCICCO, NATALIA M.
dc.creatorSILVA, ANDRE H.
dc.creatorNASCIMENTO, TATIELLE do
dc.creatorDIAS, LUIS A.P.
dc.creatorSILVA, FLAVIA R. de O.
dc.creatorRICCI-JUNIOR, EDUARDO
dc.creatorSANTOS-OLIVEIRA, RALPH
dc.creatorBERNARDES, EMERSON S.
dc.date2023
dc.date2023-04-26T19:25:45Z
dc.date2023-04-26T19:25:45Z
dc.date.accessioned2023-09-28T14:25:52Z
dc.date.available2023-09-28T14:25:52Z
dc.identifier1868-6958
dc.identifierhttp://repositorio.ipen.br/handle/123456789/34015
dc.identifier1
dc.identifier14
dc.identifier10.1186/s12645-023-00161-2
dc.identifier0000-0002-0029-7313
dc.identifier66.9
dc.identifier76
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9004224
dc.descriptionChemotherapy resistance remains a major cause of therapeutic failure in gastric cancer. The combination of genetic material such as interference RNAs (iRNAs) to silence cancer-associated genes with chemotherapeutics has become a novel approach for cancer treatment. However, finding the right target genes and developing non-toxic, highly selective nanocarrier systems remains a challenge. Here we developed a novel sialyl-Tn-targeted polylactic acid???didodecyldimethylammonium bromide nanoparticle (PLA-DDAB) nanoparticles (NPs) loaded with dsRNA targeting ST6GalNac-I and/or galectin-3 genes. Using single photon emission computed tomography (SPECT), we have demonstrated that 99mtechnetium radiolabeled sialyl-Tn-targeted nanoparticles can reach the tumor site and downregulate ST6GalNAc-I and galectin-3 RNA expression levels when injected intravenously. Furthermore, using an in vivo gastric tumor model, these nanoparticles increased the effectiveness of 5-FU in reducing tumor growth. Our findings indicate that cancer-associated glycan-targeted NPs loaded with dsRNA targeting ST6GalNAc-I and/or galectin-3 in combination with standard chemotherapy, have the potential to become a novel therapeutic tool for gastric cancer.
dc.descriptionFunda????o de Amparo ?? Pesquisa do Estado de S??o Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Cient??fico e Tecnol??gico (CNPq)
dc.descriptionFunda????o de Amparo ?? Pesquisa do Estado do Rio de Janeiro (FAPERJ)
dc.descriptionFAPESP: 12/06875-6
dc.descriptionCNPq: 300376/2017-0
dc.descriptionFAPERJ: E-26/200.815/2021; E-26/010.000981/2019
dc.format1-21
dc.relationCancer Nanotechnology
dc.rightsopenAccess
dc.subjectneoplasms
dc.subjectstomach
dc.subjectrna
dc.subjectantigens
dc.subjectchemotherapy
dc.titleDevelopment of glycan???targeted nanoparticles as a novel therapeutic opportunity for gastric cancer treatment
dc.typeArtigo de peri??dico
dc.coverageI


Este ítem pertenece a la siguiente institución